ArticleOncotarget2015
Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer.Cancer gene therapy · 2024Article
- CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue.Communications biology · 2022Article
- Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.International journal of molecular sciences · 2021Review
- Article
- Site-Specific and Common Prostate Cancer Metastasis Genes as Suggested by Meta-Analysis of Gene Expression Data.Life (Basel, Switzerland) · 2021Article
- Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.Histopathology · 2020Review
- Article
- Prognostic and clinicopathological significance of long noncoding RNA CTD-2510F5.4 in gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Article
- LncRNA NRON down-regulates lncRNA snaR and inhibits cancer cell proliferation in TNBC.Bioscience reports · 2019Article
- Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.Scientific reports · 2019Article
- Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer.Oncotarget · 2018Article
- Molecular Biomarkers in the Clinical Management of Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018Review
- The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.Oncotarget · 2018Review
- Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.BMC cancer · 2018Article
- Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A.OncoTargets and therapy · 2018Article
- Ginkgo biloba extract EGb 761-induced upregulation of LincRNA-p21 inhibits colorectal cancer metastasis by associating with EZH2.Oncotarget · 2017Article
- Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.Scientific reports · 2017Article
- The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice.Molecular diagnosis & therapy · 2017Review
- Relationship between LINC00341 expression and cancer prognosis.Oncotarget · 2017Article
- Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current prostate cancer (PCa) biomarkers such as PSA are not optimal in distinguishing cancer from benign prostate diseases and predicting disease outcome. To discover additional biomarkers, we investigated PCa-specific expression of novel unannotated transcripts. Using the unique probe design of Affymetrix Human Exon Arrays, we identified 334 candidates (EPCATs), of which 15 were validated by RT-PCR. Combined into a diagnostic panel, 11 EPCATs classified 80% of PCa samples correctly, while maintaining 100% specificity. High specificity was confirmed by in situ hybridization for EPCAT4R966 and EPCAT2F176 (SChLAP1) on extensive tissue microarrays. Besides being diagnostic, EPCAT2F176 and EPCAT4R966 showed significant association with pT-stage and were present in PIN lesions. We also found EPCAT2F176 and EPCAT2R709 to be associated with development of metastases and PCa-related death, and EPCAT2F176 to be enriched in lymph node metastases. Functional significance of expression of 9 EPCATs was investigated by siRNA transfection, revealing that knockdown of 5 different EPCATs impaired growth of LNCaP and 22RV1 PCa cells. Only the minority of EPCATs appear to be controlled by androgen receptor or ERG. Although the underlying transcriptional regulation is not fully understood, the novel PCa-associated transcripts are new diagnostic and prognostic markers with functional relevance to prostate cancer growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.